• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膜翅目毒液过敏中刺蛰激发试验的益处与局限性

Benefits and limitations of sting challenge in hymenoptera venom allergy.

作者信息

Aßmus Katharina, Meissner Markus, Kaufmann Roland, Valesky Eva Maria

机构信息

Department of Dermatology, Venereology and Allergology, University Hospital, Goethe University, Frankfurt, Germany.

出版信息

Allergol Select. 2021 Jan 18;5:45-50. doi: 10.5414/ALX02148E. eCollection 2021.

DOI:10.5414/ALX02148E
PMID:33490858
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7814776/
Abstract

The prevalence of systemic reactions to hymenoptera stings is up to 7.5%. Venom-specific immunotherapy (VIT) is an established treatment for insect venom allergy. In order to monitor the allergic status and thus the success of the therapy, controlled sting challenge under VIT continues to be the gold standard. This review deals not only with useful indications and therapeutic consequences but also with critical aspects that should be considered when performing sting challenge.

摘要

膜翅目昆虫叮咬引起全身反应的发生率高达7.5%。特异性毒液免疫疗法(VIT)是治疗昆虫毒液过敏的既定方法。为了监测过敏状态以及治疗效果,在VIT期间进行的控制性叮咬激发试验仍然是金标准。本综述不仅涉及有用的适应症和治疗结果,还涉及在进行叮咬激发试验时应考虑的关键方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b75/7814776/88325ab75c9b/allergologieselect-5-045-03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b75/7814776/87a18901fb75/allergologieselect-5-045-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b75/7814776/807d1b9ba3c4/allergologieselect-5-045-02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b75/7814776/88325ab75c9b/allergologieselect-5-045-03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b75/7814776/87a18901fb75/allergologieselect-5-045-01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b75/7814776/807d1b9ba3c4/allergologieselect-5-045-02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b75/7814776/88325ab75c9b/allergologieselect-5-045-03.jpg

相似文献

1
Benefits and limitations of sting challenge in hymenoptera venom allergy.膜翅目毒液过敏中刺蛰激发试验的益处与局限性
Allergol Select. 2021 Jan 18;5:45-50. doi: 10.5414/ALX02148E. eCollection 2021.
2
Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.在接受常规膜翅目毒液免疫治疗时仍对叮咬激发试验有反应的患者,通过增加毒液剂量得到保护。
J Allergy Clin Immunol. 2001 Dec;108(6):1027-32. doi: 10.1067/mai.2001.119154.
3
Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.膜翅目毒液免疫疗法临床疗效的预测因素。
Clin Exp Allergy. 2014;44(5):736-46. doi: 10.1111/cea.12275.
4
Deliberate hymenoptera sting challenge as a diagnostic tool in highly selected venom-allergic patients.在经过严格筛选的毒液过敏患者中,将故意进行膜翅目昆虫叮咬激发试验作为一种诊断工具。
Ann Allergy Asthma Immunol. 1995 Jul;75(1):30-2.
5
Specific Immunotherapy in Hymenoptera Venom Allergy and Concomitant Malignancy: A Retrospective Follow-up Focusing on Effectiveness and Safety.蜂类毒液过敏与合并恶性肿瘤的特异性免疫治疗:回顾性随访关注有效性和安全性。
J Investig Allergol Clin Immunol. 2017;27(6):370-377. doi: 10.18176/jiaci.0184. Epub 2017 Jul 4.
6
Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.基础血清类胰蛋白酶升高与膜翅目毒液过敏:与蜇刺反应严重程度以及毒液免疫治疗安全性和有效性的关系。
Clin Exp Allergy. 2003 Sep;33(9):1216-20. doi: 10.1046/j.1365-2222.2003.01755.x.
7
Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects.免疫治疗患者与无免疫治疗患者和无症状致敏患者之间的昆虫毒液过敏的免疫差异。
Allergy. 2018 Jun;73(6):1223-1231. doi: 10.1111/all.13368. Epub 2017 Dec 19.
8
Insect sting allergy with negative venom skin test responses.毒液皮肤试验反应阴性的昆虫叮咬过敏
J Allergy Clin Immunol. 2001 May;107(5):897-901. doi: 10.1067/mai.2001.114706.
9
Clinical aspects of hymenoptera venom allergy and venom immunotherapy.膜翅目昆虫毒液过敏与毒液免疫疗法的临床方面
Eur Ann Allergy Clin Immunol. 2019 Nov;51(6):244-258. doi: 10.23822/EurAnnACI.1764-1489.113.
10
Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.蜜蜂毒液和黄蜂毒液的免疫疗法在疗效和安全性方面存在差异。
J Allergy Clin Immunol. 1992 Feb;89(2):529-35. doi: 10.1016/0091-6749(92)90319-w.

引用本文的文献

1
StingReady: A Novel Device for Controlled Insect Sting Challenge-From Field Capture to Clinical Application.StingReady:一种用于可控昆虫叮咬激发试验的新型装置——从野外捕获到临床应用
Toxins (Basel). 2025 May 22;17(6):260. doi: 10.3390/toxins17060260.
2
Hymenoptera Venom Immunotherapy in Dogs: Safety and Clinical Efficacy.犬类的膜翅目毒液免疫疗法:安全性与临床疗效
Animals (Basel). 2023 Sep 23;13(19):3002. doi: 10.3390/ani13193002.
3
Venom Immunotherapy: Immune Mechanisms of Induced Protection and Tolerance.毒液免疫治疗:诱导保护和耐受的免疫机制。

本文引用的文献

1
Safety and Effectiveness of a 3-Day Rush Insect Venom Immunotherapy Protocol.3 天速成昆虫毒液免疫治疗方案的安全性和有效性。
Int Arch Allergy Immunol. 2020;181(2):111-118. doi: 10.1159/000503965. Epub 2019 Dec 3.
2
EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy.EAACI 指南:变应原免疫治疗:蜂类毒液过敏。
Allergy. 2018 Apr;73(4):744-764. doi: 10.1111/all.13262. Epub 2017 Dec 5.
3
Self-medication of anaphylactic reactions due to Hymenoptera stings-an EAACI Task Force Consensus Statement.蜂蜇后过敏反应的自我药物治疗:一项 EAACI 共识声明。
Cells. 2021 Jun 22;10(7):1575. doi: 10.3390/cells10071575.
4
Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy.特异性免疫疗法和蜂蜇激发试验对膜翅目毒液过敏患者生活质量的影响。
World Allergy Organ J. 2021 Apr 21;14(5):100536. doi: 10.1016/j.waojou.2021.100536. eCollection 2021 May.
Allergy. 2016 Jul;71(7):931-43. doi: 10.1111/all.12908. Epub 2016 Apr 29.
4
Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy.蜜蜂毒液免疫疗法起始阶段与不良全身反应相关的免疫学和临床因素。
Clin Exp Allergy. 2015 Oct;45(10):1579-89. doi: 10.1111/cea.12582.
5
[Sting challenge: indications and execution].[蜇刺激发试验:适应证与实施方法]
Hautarzt. 2014 Sep;65(9):796-801. doi: 10.1007/s00105-014-2779-2.
6
Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations.变应原免疫治疗在克隆性肥大细胞疾病患者中的疗效、安全性和实际考虑。
J Allergy Clin Immunol Pract. 2013 Sep-Oct;1(5):474-8. doi: 10.1016/j.jaip.2013.06.014. Epub 2013 Aug 30.
7
Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase.血管紧张素转换酶抑制剂不会损害膜翅目毒液免疫治疗起始阶段的安全性。
Clin Exp Allergy. 2014;44(5):747-55. doi: 10.1111/cea.12276.
8
Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.膜翅目毒液免疫疗法临床疗效的预测因素。
Clin Exp Allergy. 2014;44(5):736-46. doi: 10.1111/cea.12275.
9
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.蜂毒免疫治疗的临床疗效:变应原免疫治疗临床实践指南欧洲专家组关于昆虫毒液过敏的前瞻性观察性多中心研究。
PLoS One. 2013 May 20;8(5):e63233. doi: 10.1371/journal.pone.0063233. Print 2013.
10
Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom.耐受黄蜂蜇刺激发试验可改善对黄蜂毒液过敏患者的健康相关生活质量。
J Allergy Clin Immunol. 2013 Aug;132(2):489-90. doi: 10.1016/j.jaci.2013.03.010. Epub 2013 Apr 30.